SLC6A3 and Parkinson disease: Nonetheless, a more recent analysis performed in a significantly larger and homogeneous patient population showed a better PET ligand binding to DAT in LRRK2 G2019S non-symptomatic carriers with respect to sporadic PD patients, which has been interpreted as being due to a slower DAT decline or a reduced DA release [69].